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Edited by Robert BaroukiAbstract We have investigated the acute eﬀects of 17-b-estra-
diol (E2) on K
+ channels in MCF-7 breast epithelial cancer cells.
E2 induced a rapid and irreversible augmentation of the K
+ cur-
rent for all membrane potentials superior to 25 mV. The eﬀect
of E2 was sensitive to Iberiotoxin, Charybdotoxin and TEA and
can be elicited in the presence of the anti-estrogen ICI 182 780 or
be mimicked by the membrane impermeant form E2/BSA. Fur-
thermore, E2/BSA was able to stimulate cell proliferation in a
maxi-K inhibitors-sensitive manner. Thus, these results permit
us to identify the maxi-K channel as the molecular target of
E2 that regulates cell proliferation independently of the estrogen
receptor.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The steroid hormone 17-b-estradiol (E2) is a key growth reg-
ulator, diﬀerentiating and functioning in a wide array of target
tissues, including the mammary gland, where it interacts with
other hormones, growth factors and cytokines [1]. E2 is in-
volved in normal breast development, where it stimulates
growth of the ductal system, although clinical and experimen-
tal data have clearly established that exposure to estrogens is
the leading cause of sporadic female breast cancer [2].
The predominant biological eﬀects of E2 have traditionally
been considered to be based on its interaction with intracellu-
lar estrogen receptors (ERs). These act via the regulation of
transcriptional processes, involving nuclear translocation,
binding to speciﬁc estrogen response elements (EREs) and ulti-
mately regulate gene expression [1,3]. However, numerous
studies have shown that steroid hormones and particularly
E2 are able to elicit cellular responses that are too rapid to
be mediated by the activation of transcription and traduction
mechanisms. These observations permitted the proposition of
an alternative (non-genomic) pathway that would be responsi-
ble, at least in part, for the cellular activation following steroid
stimulation [4–6]. Various alternative eﬀects of steroids have
been reported including the activation of membrane receptors,*Corresponding author. Fax: +33 322827644.
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doi:10.1016/j.febslet.2005.02.085the modulation of ion channels or eﬀects such as the regulation
of gene transcription secondary to the activation of signalling
cascades (e.g., cAMP or MAP-Kinase cascades) [7].
Over the past few years, many studies have been carried out
on breast cancer cell lines in order to elucidate the role of E2 in
the emergence and the physiopathology of breast cancer [1].
However, to our knowledge, all these studies were conducted
with regard to the classical genomic eﬀects of E2, without con-
sidering the eventual participation of an alternative pathway in
the regulation of the processes involved in the control of the
cell cycle. Furthermore, many other studies have pointed out
the role supported by ion channels, mainly potassium chan-
nels, in the rapid onset of oncogenic cellular processes [8]. In
breast cancer cells, we and others have reported that a pharma-
cological blockade of K+ channels leads to the inhibition of
cell proliferation. This result is, thus, in favour of a central role
of K+ ion ﬂux across the plasma membrane in the progression
through the cell cycle [9–13].
The aim of the present study was to investigate the acute ef-
fects of E2 in the MCF-7 cell line with regard to its eventual
eﬀect on K+ channels and cell proliferation through the alter-
native pathway. We show, for the ﬁrst time, that E2 and E2/
BSA increase the large conductance Ca2+-dependent K+
(maxi-K) channels activity in breast cancer cells through a
non-genomic pathway.2. Materials and methods
2.1. Cell culture
The breast cancer cell line MCF-7 was purchased from the American
TypeCulture Collection (ATCC, LGCPromochem,MolsheimFrance).
Cells were grown in Eagles Minimal Essential Medium (EMEM) sup-
plemented with 5% foetal calf serum (FCS), 2 mM L-glutamine,
0.06% HEPES Buﬀer and a mixture of penicillin (50 UI/ml)/streptomy-
cin (50 lg/ml). The EMEM solution was renewed every two days. Cells
were grown in an atmosphere saturated with humidity at 37 C and 5%
CO2. MCF-7 cells were tested between passage 147 and 200.
2.2. Electrophysiology
For electrophysiological analysis, cells were cultured in 35 mm Petri
dishes at a density of 5 · 104 cells 2 days before patch clamp experi-
ments. Currents were recorded in voltage-clamp mode, using an
Axopatch 200 B patch-clamp ampliﬁer (Axon Instruments, Burlin-
game, CA) and a Digidata 1200 interface (Axon Instruments). PClamp
software (v. 6.03, Axon Instruments) was used to control voltage, as
well as to acquire and analyze data. The whole-cell mode of the
patch-clamp technique was used with 3–5 MX resistance borosilicate
ﬁre-polished pipettes (Hirschmann, laborgerate). Seal resistance was
typically in the 10–20 GX range. The maximum uncompensated series
resistance was <10 MX during whole-cell recordings, so the voltageblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of E2 on K
+ current in MCF-7 breast cancer cell line. (A)
Typical examples of current traces recorded in control conditions and
after E2 perfusion at a concentration of 10 nM. The holding potential
was 40 mV and 300 ms voltage steps were applied from 100 to
+100 mV in 10 mV increments. (B) Current/voltage relationships were
recorded by measuring the maximum amplitude of IK at the end of the
depolarization as shown by the arrow in (A) before (n) and after (d)
2996 G. Coiret et al. / FEBS Letters 579 (2005) 2995–3000error was < 5 mV for a current amplitude of 500 pA. Recordings where
series resistance resulted in errors greater than 5 mV in voltage com-
mands were discarded. Whole-cell currents were allowed to stabilize
for 5 min before K+ currents were measured.
In order to evaluate the eﬀect of pharmacological agents on the cur-
rent, we used a depolarizing step from 100 to +100 mV during
200 ms.
Cells were allowed to settle in Petri dishes placed at the opening of a
250-lm-inner diameter capillary for extra-cellular perfusions. The cell
under investigation was continuously superfused with control or test
solutions. All electrophysiological experiments were performed at
room temperature (20–22 C).
2.3. Solutions
External and internal solutions had the following compositions (in
mM). External: NaCl 145, KCl 5, CaCl2 2, MgCl2 1, and HEPES 10
at pH 7.4 (NaOH), and osmolarity 300 mOsm. Internal: KCl 150,
HEPES 10, EGTA 0.1, MgCl2 2 at pH 7.2 (KOH), osmolarity 292
mOsm, measured with a freezing-point depression osmometer. Char-
ybdotoxin (ChTx) and Iberiotoxin (IbTx) (Calbiochem) were made
up in BSA 1%, HEPES 5 mM (pH 7.2). E2 and ICI 182 780 (Sigma,
France) were made up in ethanol. Final concentrations were obtained
by appropriate dilution in an external control solution. b-Estradiol 6-
(O-carboxymethyl)oxime: BSA (E2/BSA, Sigma) contained 35 mol of
steroid per mole of BSA and was dissolved in water.
2.4. Cell proliferation assay
Cells were seeded in 96-well plates in EMEM with 5% FCS. After
48 h, cells were washed with PBS and incubated with EMEM without
FCS. After a 24 h starvation period, cells were washed and incubated
with 5% dextran-coated charcoal treated FCS (DCCFCS, to remove
any steroids) in phenol red free EMEM, and pre-incubated with vary-
ing doses of E2 or E2/BSA alone or in association with IbTx, ChTx and
TEA. The medium was changed every other day. After 3 days of treat-
ment, the cell number was determined by a colorimetric method
(CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay).
The potential toxicity of the various drugs was assessed by comparing
the proliferation rate of the cells in FCS-free culture medium in the ab-
sence or in the presence of the drugs.
2.5. Statistical analysis
Results were expressed as means ± S.D. Experiments were repeated
at least three times. The Students t test was used to compare treat-
ment means with electrophysiological control means (paired t test)
and proliferation (unpaired t test) assays. P < 0.05 was considered
as signiﬁcant.the perfusion of E2 (10 nM). (C) Time course of the increase in IK by
E2. (D) Dose-dependent increase of IK by E2. The number of cells
recorded for each E2 concentration is indicated on the graph.3. Results
3.1. E2 potentiates K
+ channel activity in MCF-7 cells
The acute eﬀects of E2 on K
+ channels activity in MCF-7
breast epithelial cancer cells were investigated using the
patch-clamp technique in the whole-cell conﬁguration. The
cell membrane was held at 40 mV and stepped from 100
to +100 mV in 10 mV increments for 250 ms (Fig. 1A).
Extra-cellular perfusion of E2 (10 nM) increased the K
+ cur-
rent (IK) amplitude (Fig. 1A). Analysis of the current–voltage
relationships showed that the current potentiation by E2 was
observed for all membrane potentials superior to 25 mV
(Fig. 1B). The eﬀect of E2 was generally rapid and peaked at
3.4 ± 2.6 min (n = 11, Fig. 1C). Once manifested, the E2 action
could not be reversed even by 20–30 min of continuous wash-
ing (data not shown). The eﬀect of E2 was dose-dependent,
with an EC50 of 80 pM (n = 39, Fig. 1D). The IK potentiation
appeared with 30 pM E2 and the maximal eﬀect was obtained
with 10 nM. Although variability analysis suggests that the ef-
fects at various concentration levels were not statistically dif-
ferent, there was an obvious trend toward an increase ineﬀects with increasing concentrations. For all the further
experiments, 10 nM of E2 was chosen.
3.2. E2 activates the maxi-K channels
To test whether E2 can selectively potentiate maxi-K chan-
nels, we used three diﬀerent inhibitors of the maxi-K channel:
Iberiotoxin (IbTx), Charybdotoxin (ChTx) and TEA. The
extra-cellular perfusion of E2 (10 nM) increased IK by 27.2%,
the application of IbTx (100 nM) in the presence of E2 com-
pletely suppressed the E2 eﬀect (n = 4, Fig. 2A). Furthermore,
the E2 eﬀect also decreased when perfused with ChTx (50 nM)
(n = 3, Fig. 2B) or TEA (500 lM) (n = 3, Fig. 2C). We also
tested the following protocol, where the cell was treated ﬁrst
by IbTx, ChTx or TEA to block maxi-K current and then
E2 was perfused with these drugs to determine whether the in-
crease eﬀects of E2 could be observed during a blockade of
maxi-K channels. As shown in Fig. 2D–F, the application of
100 nM IbTx revealed a maxi-K which was 26% of the total
IK (n = 3, Fig. 2D). The application of E2 in the presence of
Fig. 2. Pharmacological characterization of K+ channel type sensitive to E2. (A)–(C) Time courses of the evolution in IK amplitude. Depolarizing
voltage steps were applied from 100 to +100 mV for 300 ms every 30 s. After stabilization of IK in control conditions, E2 (10 nM) was ﬁrstly
perfused alone and then together with K+ channels blockers: IbTx (100 nM, A), ChTx (50 nM, B) and TEA (500 lM, C). IK amplitude was measured
at the end of the depolarization step. (D)–(F) In this case, K+ channel blockers IbTx (100 nM, D), ChTx (50 nM, E) and TEA (500 lM, F) were
perfused before the application of E2 (10 nM).
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were obtained in the presence of 50 nM ChTx (n = 3, Fig. 2E)
or 500 lM TEA (n = 4, Fig. 2F).
3.3. The E2 eﬀect was extra-cellular and independent of the
estrogen receptor
To investigate whether the potentiation eﬀect of E2 on the
maxi-K was mediated through ERs, the eﬀect of superfusion
with the speciﬁc antagonist of E2 receptor was tested. No sig-
niﬁcant change in IK was observed after the perfusion of the
pure ER antagonist ICI 182 780 (1 lM) and the eﬀect of E2
on the maxi-K current was not prevented by this inhibitor. In-
deed, E2 (10 nM) was still able to increase IK by 9 ± 5.6% even
in the presence of ICI 182 780 (n = 4, Fig. 3Aab).
To determine whether penetration of E2 through the cell
membrane was necessary for the steroid to be eﬀective, we ana-
lysed the actions of the membrane impermeant protein conju-
gates E2/BSA on the IK in MCF-7 cells (Fig. 3Bab). As shown
in Fig. 3Ba, the IK increased after perfusion with 10 nM E2/
BSA. Indeed, the IK increased by 20 ± 7% (n = 5) from controlvalues by 50 s of perfusion with E2/BSA (Fig. 3Bb). Moreover,
E2/BSA 10 nM failed to increase maxi-K current amplitude
when perfused in the presence of 500 lM TEA (n = 4, Fig.
3C) or 50 nM ChTx (n = 3, Fig. 3D).
3.4. Eﬀects of the modulation of maxi-K channels by E2 on
MCF-7 cell proliferation
It is well known that E2 increases the breast cancer cell pro-
liferation and that this eﬀect has only been attributed to a
genomic pathway. We have previously reported that the
expression of maxi-K channels was cell cycle-dependent in
MCF-7 cells [11]. Thus, we investigated whether the prolifera-
tive eﬀect of E2 was, in part, due to the activation of maxi-K
channels. Both E2 and E2/BSA increased cell proliferation in
a dose-dependent manner when compared to the control
(DCCFCS) with an EC50 in the region of 100 and 80 pM for
E2 and E2/BSA, respectively (Fig. 4A–C). We then investigated
the eﬀect of the most potent maxi-K channel blockers (IbTx,
ChTx and TEA) on cell proliferation mediated by E2 and E2/
BSA. Neither IbTx (100 nM), ChTx (50 nM), nor TEA
Fig. 3. E2 modulates maxi-K channels through an ER-independent pathway. (A) Application of a depolarizing voltage step from 100 to +100 mV
induced a voltage-activated K+ current. (a) Current traces obtained in control conditions (1), in the presence of ICI 182 780 (2) and in the presence of
both ICI 182 780 and E2 (10 nM) (3). (b) Time course of the increase in IK by E2 in the presence of ICI 182 780. E2 (10 nM) was still able to increase
IK by 9 ± 5.6% even in the presence of a speciﬁc ER antagonist (ICI 182 780) at a high concentration (1 lM, n = 4). (B) Extra-cellular perfusion of E2/
BSA at a concentration of 10 nM increased IK by 12.7 ± 4% (n = 4). (a) Representative current traces from a single MCF-7 cell perfused with E2/BSA
10 nM. The voltage-dependent current was elicited by a depolarizing voltage step from 100 to +100 mV for 300 ms; (1) control; (2) E2/BSA
(10 nM). (b) Time course of the IK increase by E2/BSA (10 nM). (C, D) E2/BSA (10 nM) failed to increase IK when perfused in the presence of TEA
(500 lM, C) and ChTx (50 nM, D).
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(n = 8, Fig. 4D), while they reduced proliferation induced by
E2/BSA (n = 8, Fig. 4D). Indeed, cell proliferation mediated
by E2/BSA was reduced by 4.4%, 9.7% and 10.2% by IbTx,
ChTx and TEA, respectively. In control conditions, MCF-7
cell proliferation was inhibited only in the presence of TEA,
but not by IbTx or ChTx. The reduction of cell proliferation
induced by these drugs was due to their K+ channels antago-
nist properties since no toxicity was observed for any of the
maxi-K channel blockers tested. Indeed, when using FCS-free
culture medium, the number of MCF-7 cells obtained after the
incubation period with these blockers was not signiﬁcantly dif-
ferent from the control condition (data not shown).4. Discussion
We have recently reported maxi-K channels in MCF-7 cells
[11]. To our knowledge, the acute eﬀects of estrogens onvoltage-gated K+ channels have not previously been investi-
gated in breast cancer cells. In this study, we provide the ﬁrst
evidence that epithelial breast maxi-K channels are rapidly
activated by low concentrations of E2. This activation is inde-
pendent of ERs and can be triggered by E2 conjugated to a
membrane-impenetrable carrier protein (E2/BSA). Both E2
and E2/BSA failed to increase the maxi-K current when per-
fused in the presence of maxi-K channel blockers. Further-
more, IbTx, ChTx and TEA inhibited cell proliferation
mediated by E2/BSA. Thus, in addition to this genomic eﬀect,
E2 causes, by a non-genomic pathway, an increase in cell pro-
liferation via a direct and/or indirect activation of maxi-K
channels.
Our experiments show that the amplitude of the current sup-
ported by maxi-K channels is rapidly and markedly enhanced
by E2 or by its impermeant analogue E2/BSA in a concentra-
tion-dependent manner. Furthermore, dose-eﬀect experiments
show that the maxi-K channels in MCF-7 cells are highly sen-
sitive to E2 since the EC50 was 26 000-fold lower than that
Fig. 4. Eﬀects of E2, E2/BSA and maxi-K channel blockers on cell proliferation. All experiments were performed in the presence of steroid-free FCS
(DCCFCS, see Section 2). Bars represent 8 independent experiments ± S.D. The experimental group medians marked by asterisks are signiﬁcantly
diﬀerent from the control median (\ P < 0.05; \\ P < 0.01, \\\ P < 0.001). (A, B) Eﬀects of various concentrations of E2 (A) and E2/BSA (B) on MCF-
7 cell proliferation. (C) Dose–response curves showing the proliferative eﬀect of E2 (n) and E2/BSA (s). Values are taken from the two graphs shown
in A and B. (D) Eﬀect of IbTx, ChTx and TEA on cell proliferation in the control conditions (DCCFCS) and combined with E2 or E2/BSA.
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Estrogen receptors exist in the epithelial breast cancer cells
MCF-7 [16] and their activation results in increased cell prolif-
eration [1], however, our results demonstrate that no ER is in-
volved because the application of the anti-estrogen ICI 182 780
[17] did not alter the increase in maxi-K channel activity by E2.
Taken together, these results are in agreement with an alterna-
tive modulation of maxi-K channels by estrogens by direct or
indirect interaction and provide evidence of an extra-cellular
estradiol action site perhaps within the extra-cellular loop of
the maxi-K channel b1 subunit [14,18]. Indeed, non-genomic
eﬀects of E2 on maxi-K current have been demonstrated by
its ability to induce channel openings when the channel a sub-
unit is associated with either the accessory b1 or the b4 sub-
unit, but not in their absence [14,18,19]. More recently, using
HEK-293 cells transfected with maxi-K channels, Korovkina
et al. [20] demonstrated that estrogens bind to maxi-K chan-
nels and may directly regulate channel function. Estrogens
are also known to regulate maxi-K channel activity by several
cellular signalling mechanisms: (i) the activation of nitric oxidesynthase (NOS) in uterine cells [21]; (ii) the cGMP-dependent
phosphorylation in coronary arteries [4,15]. Nevertheless, con-
sidering that the E2 eﬀect is not prevented by ICI 182 780, we
can rule out the possible implication of protein kinase G and
NOS pathways. However, further mechanistic studies are re-
quired to determine a direct and/or indirect eﬀect of E2 on
maxi-K channels on MCF-7 cells.
An important result is that E2/BSA is able to increase the
MCF-7 cells proliferation in a dose-dependent manner, as
was the case with E2. Moreover, the growth activation pro-
duced by E2/BSA was reduced when blocking maxi-K channel
activity, hence suggesting that maxi-K channels constitute one
pathway by which estrogens increase cell proliferation. The
non-eﬀect of IbTx, ChTx or TEA on cell proliferation medi-
ated by E2 is probably due to a genomic eﬀect of E2. Indeed,
it has been reported that estrogens regulate the expression of
several K+ channel types [22–24]. In this way, long-term expo-
sure to estrogens up-regulates the mRNA expression levels of a
and b-subunits of maxi-K [22,25], the mRNA level of SUR2A
subunit increasing the expression of the KATP channels [23]. In
3000 G. Coiret et al. / FEBS Letters 579 (2005) 2995–3000MCF-7 cell line, we have reported that proliferation control
depends on K+ channel activity according to the ‘‘membrane
potential’’ model [12]. Thus, K+ channel blockers which
depolarize the membrane potential, also inhibit proliferation
[12]. As MCF-7 cells express numerous K+ channels, E2 could
up-regulate the expression of some of them, thereby inducing a
suﬃcient hyperpolarization to stimulate cell proliferation.
Thus, the lack of the IbTx, ChTx and TEA eﬀects on cell pro-
liferation mediated by E2, suggests that the membrane poten-
tial was mainly determined by another K+ channel type
which is insensitive to these drugs.
In summary, we have found that E2 causes an increase in
MCF-7 cell proliferation via an opening of maxi-K channels.
Our results also suggest that ERs are not involved and thus
that this regulation occurs independently of the classical geno-
mic pathway. The modulation of maxi-K channel by E2 and its
role in cell proliferation might explain the ineﬃciency of treat-
ments against breast cancer that just rest on the use of ER
antagonists and, therefore, could be taken into consideration.
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